COSCIENS Biopharma (CSCIF) AI Stock Analysis

COSCIENS Biopharma

(Other OTC:CSCIF)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Improving Gross MarginThe substantial gross-margin improvement indicates better economics on the company’s current revenue base. If maintained, stronger margins can reduce the operating gap, improve the value of future growth, and support a more durable path toward eventual profitability.

Negative Factors

Persistent UnprofitabilityDespite improved losses, the company remains deeply unprofitable and generates strongly negative returns on equity. The magnitude of these deficits means the business has not yet demonstrated a self-sustaining earnings model, leaving profitability improvement as a central fundamental risk.

COSCIENS Biopharma (CSCIF) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $6.08M
Dividend Yield: ―
Average Volume (3M): 781
Price to Earnings (P/E): -0.5
Beta (1Y): 1.75
Revenue Growth: -12.31%
EPS Growth: 75.16%
Country: US
Employees: 28
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Pharmaceuticals

COSCIENS Biopharma Business Overview & Revenue Model

Company Description

COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, the United Kingdom, and internationally. It operates through Active I...

COSCIENS Biopharma Risk Analysis

COSCIENS Biopharma disclosed 52 risk factors in its most recent earnings report. COSCIENS Biopharma reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks

1.In the event that we fail to satisfy any of the listing requirements of Nasdaq, including the Bid Price Rule, Nasdaq may reject our application to list on Nasdaq.Q4, 2023

2.We may be unable to successfully integrate our businesses with Ceapro's and realize the anticipated benefits of the Plan of Arrangement. The failure to successfully integrate the businesses of Aeterna and Ceapro could have a material adverse effect on the market price of the Common Shares following completion of the Plan of Arrangement.Q4, 2023

3.We cannot provide any assurance that our systems, procedures and controls will be adequate to support the expansion of operations and associated increased costs and complexity following and resulting from the Plan of Arrangement with Ceapro.Q4, 2023

COSCIENS Biopharma Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

CSCIF against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TSE:GLOW	53Neutral	CAD 7.70M	-50.00	-10.61%	―	56.41%	91.30%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TSE:MDMA	50Neutral	CAD 18.57M	-11.41	-72.15%	―	224.46%	28.37%
TSE:MRVL	46Neutral	CAD 7.56M	-4.49	39.05%	―	―	25.70%
TSE:BETR	43Neutral	CAD 154.50M	-11.36	34.90%	―	―	-266.67%
TSE:PHRM	34Underperform	CAD 5.01M	-8.33	-75.59%	―	―	75.84%

* Healthcare Sector Average

Performance Comparison

CSCIF and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
CSCIF	Cosciens Biopharma Inc.	6.10	-1.40	-18.67%
TSE:BETR	Betterlife Pharma Inc.	0.25	0.19	316.67%
TSE:PHRM	PharmaTher Holdings Ltd	0.06	-0.06	-50.00%
TSE:GLOW	Glow Lifetech Corp	0.04	-0.01	-20.00%
TSE:MRVL	Marvel Biosciences Corp	0.12	-0.10	-45.45%
TSE:MDMA	PharmAla Biotech Holdings, Inc.	0.17	0.05	41.67%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

COSCIENS Biopharma AI Stock Analysis